meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs regorafenib
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
ECOG 0
ECOG 1
Gender, female
Gender, male
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
DCR
mCRC - 2nd line (L2)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
versus BSC
durvalumab plus tremelimumab vs. BSC
1
certainty unassessable
+316%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open